Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients — CLAIM

Chronic Obstructive Pulmonary Disease, COPD Clinical Trial

Official title:
A Randomized, Double-blinded, Single-center, Placebo Controlled, Cross-over Study to Assess the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) on Cardiac Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status Completed

Clinical Trial Summary

This mechanistic study is a single-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effect of dual bronchodilation with QVA149 on cardiac and lung function parameters in hyperinflated COPD patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Obstructive Pulmonary Disease, COPD
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive

Clinical Trial Details

NCT number	NCT02442206
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 4
Start date	May 18, 2015
Completion date	May 15, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00108823` - The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)	Phase 3
Completed	`NCT03064113` - Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)	Phase 2
Completed	`NCT00496470` - Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.	Phase 4
Completed	`NCT03095456` - Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD	Phase 3
Completed	`NCT02615795` - Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease	N/A
Completed	`NCT02449018` - A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251	Phase 2